• / Free eNewsletters & Magazine
  • / My Account
Home>Gilead Cell-Therapy Drug Yescarta Gets FDA Approval

Gilead Cell-Therapy Drug Yescarta Gets FDA Approval

3party Content

Thu, 19 Oct 2017

By Jonathan D. Rockoff Gilead Sciences Inc.'s $11 billion bet on Kite Pharma Inc. is poised to pay off, with the approval Wednesday of Kite's flagship cell-therapy treatment for advanced lymphoma patients. The therapy, known as a Car-T treatment, uses genetically engineered T-cells to attack the

©2017 Morningstar Advisor. All right reserved.